Article info

Download PDFPDF

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases
Free

Authors

  1. Correspondence to Professor John D Isaacs, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK; john.isaacs{at}newcastle.ac.uk
View Full Text

Citation

Krieckaert CL, van Tubergen A, Gehin JE, et al
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

Publication history

  • Received January 24, 2022
  • Accepted April 6, 2022
  • First published May 12, 2022.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.